- Home
- QSI vs MNPR Comparison
QSI vs MNPR Comparison
Compare QSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- MNPR
- Stock Information
- Founded
- QSI 2013
- MNPR 2014
- Country
- QSI United States
- MNPR United States
- Employees
- QSI N/A
- MNPR N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- MNPR Health Care
- Exchange
- QSI Nasdaq
- MNPR Nasdaq
- Market Cap
- QSI 219.8M
- MNPR 249.5M
- IPO Year
- QSI N/A
- MNPR 2019
- Fundamental
- Price
- QSI $1.68
- MNPR $31.73
- Analyst Decision
- QSI Strong Buy
- MNPR Strong Buy
- Analyst Count
- QSI 3
- MNPR 5
- Target Price
- QSI $2.38
- MNPR $59.50
- AVG Volume (30 Days)
- QSI 11.2M
- MNPR 18.2K
- Earning Date
- QSI 05-15-2025
- MNPR 05-13-2025
- Dividend Yield
- QSI N/A
- MNPR N/A
- EPS Growth
- QSI N/A
- MNPR N/A
- EPS
- QSI N/A
- MNPR N/A
- Revenue
- QSI $3,443,000.00
- MNPR N/A
- Revenue This Year
- QSI $151.18
- MNPR N/A
- Revenue Next Year
- QSI $172.07
- MNPR N/A
- P/E Ratio
- QSI N/A
- MNPR N/A
- Revenue Growth
- QSI 167.94
- MNPR N/A
- 52 Week Low
- QSI $0.61
- MNPR $1.72
- 52 Week High
- QSI $5.77
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- QSI 56.91
- MNPR 37.28
- Support Level
- QSI $1.45
- MNPR $34.02
- Resistance Level
- QSI $2.15
- MNPR $36.82
- Average True Range (ATR)
- QSI 0.20
- MNPR 3.54
- MACD
- QSI 0.02
- MNPR -0.71
- Stochastic Oscillator
- QSI 43.71
- MNPR 27.91
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.